Vorinostat

Koneksa Raises $45M Series C Financing to Accelerate Expansion of Digital Biomarker Platform

Retrieved on: 
Monday, February 7, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Industry, Senior, Biomarker, Vorinostat, Takeda, Algorithm, Solution, Therapy, CMO, Disease management, Secondary research, Technology, Patient, Foundation, National, Foresite Capital, CEO, DNA, Adoption, Drug development, Pharmacogenomics, Partnership, Clinical and Translational Science, Matrix, Digital, COVID-19, Medical imaging, Pharmaceutical industry, Novartis, Merck

As part of the financing, Karan Takhar, Senior Managing Director at Matrix will join Koneksas Board of Directors.

Key Points: 
  • As part of the financing, Karan Takhar, Senior Managing Director at Matrix will join Koneksas Board of Directors.
  • The funding will expand Koneksas digital biomarker technology platform and development of the self-service capabilities of its clinical data integration solutions.
  • Koneksa will also expand its scientific team to accelerate digital biomarker development and evidence generation.
  • We are excited to work alongside Chris and the Koneksa team to accelerate their impact on patients and clinical science.

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Product, Incidence, Roger Hawkins (drummer), Lymphocytopenia, Degenerative disease, Kyowa Hakko Kirin, Asia, Neurology, FDA, Disease, Itch, Sleep, Lymph, Research, MF, Weakness, Non-Hodgkin lymphoma, Blood, B-cell lymphoma, Engineering, Cutaneous T cell lymphoma, Medication package insert, T-cell lymphoma, Patient, Life, CC, Lymphocyte, Family, Saint Louis Hospital (Bangkok), ORR, Diagnosis, Dermatitis, Erythroderma, Vorinostat, Skin, SS, Histone deacetylase inhibitor, Kirin, Pain, Adult, Rash, NHL, CCR4, Malignancy, Mycosis fungoides, Nephrology, Hair loss, EORTC, Hospital, Safety, Pharmaceutical industry, Vaccine, Medical imaging, Mycosis Fungoides (MF) and Sézary syndrome (SS), POTELIGEO, Kyowa Kirin, MYCOSIS FUNGOIDES (MF) AND SéZARY SYNDROME (SS), POTELIGEO, KYOWA KIRIN

Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).

Key Points: 
  • Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).
  • The best overall response rate (ORR) seen in the real-life study was 47.0% in MF patients and 68.3% in SS patients.
  • In contrast, the ORRb in MAVORIC was 21% and 37%, respectively.1,2 Of the 124 patients who received POTELIGEO treatment in the study, 44% were MF patients and 56% were SS patients.
  • Its heartening to see this new real world data, which reinforces what weve seen previously in clinical trials.

Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients

Retrieved on: 
Thursday, June 10, 2021
Oncology, Health, Clinical trials, Research, Pharmaceutical, Science, Orphan drugs, Drugs, Lymphoma, Clinical medicine, Antineoplastic drugs, Health, Cutaneous T cell lymphoma, Mogamulizumab, Vorinostat, Mycosis fungoides, Mycosis Fungoides (MF) and Sézary syndrome (SS), POTELIGEO, Kyowa Kirin, MYCOSIS FUNGOIDES (MF) AND SéZARY SYNDROME (SS), POTELIGEO, KYOWA KIRIN

We know that increasing levels of malignant T-cells in the blood correlate with increased risk of CTCL disease progression and an overall reduction in patient survival.

Key Points: 
  • We know that increasing levels of malignant T-cells in the blood correlate with increased risk of CTCL disease progression and an overall reduction in patient survival.
  • Treatment with mogamulizumab has also been shown to be more effective in CTCL patients who have blood involvement as part of their disease and treatment with mogamulizumab also generates quality of life benefits for CTCL patients with blood involvement.
  • This new information underlines the importance of blood monitoring in the clinical management of CTCL patients.
  • Statistically significant differences in quality of life were seen for patients with blood involvement, with patients treated with mogamulizumab seeing improvements in the Skindex-29 and ItchyQoL questionnaires, compared to vorinostat.

Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO

Retrieved on: 
Monday, June 4, 2018
Medicine, Monoclonal antibodies, Lymphoma, Clinical medicine, Mogamulizumab, Chemistry, Orphan drugs, Antineoplastic drugs, Cutaneous T cell lymphoma, Kyowa Hakko Kirin, Vorinostat, Antibody

MF and SS are the most common subtypes of cutaneous T-cell lymphoma (CTCL).

Key Points: 
  • MF and SS are the most common subtypes of cutaneous T-cell lymphoma (CTCL).
  • Infusion reaction and rash were the most common adverse events associated with mogamulizumab.
  • Mogamulizumab was produced using Kyowa Hakko Kirin's proprietary POTELLIGENT platform, which is associated with enhanced antibody-dependent cellular cytotoxicity.
  • The study was conducted in the U.S., Europe, Japan and Australia, and randomized 372 patients to receive either mogamulizumab or vorinostat.